RxDoctor Payments Data

Braden Coleman, MD

Family Medicine · Victoria, TXNPI 1780033043

Payments from drug & device makers

$7,675in general payments, 2019–2025

Across 496 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$711
  • Pfizer$684
  • Lilly USA, LLC$455
  • Boehringer Ingelheim$419
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,59699%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,675 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$60,627
Medicare patients
148
Services billed
1,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$93,942
MounjaroTirzepatide84$89,274
JardianceEmpagliflozin66$85,600
RybelsusSemaglutide32$55,463
Soliqua 100-33Insulin Glargine/Lixisenatide40$45,705
JanuviaSitagliptin Phosphate23$35,339
FarxigaDapagliflozin Propanediol25$31,824
XareltoRivaroxaban26$31,579
EliquisApixaban31$30,041
Tresiba Flextouch U-200Insulin Degludec12$29,550
MyrbetriqMirabegron14$11,919
VascepaIcosapent Ethyl12$11,656
GlyxambiEmpagliflozin/Linagliptin11$11,544
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,153
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,091$149,405116 claims
Boehringer IngelheimJardiance, Glyxambi$419$97,14477 claims
Lilly USA, LLCMounjaro$455$89,27484 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$246$45,70540 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$711$44,48958 claims
MerckJanuvia$187$35,33923 claims
PfizerEliquis$684$30,04131 claims
Astellas Pharma US IncMyrbetriq$132$11,91914 claims
GSKTrelegy Ellipta$353$9,15314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →